Multivariable regression analysis of febrile neutropenia occurrence in early breast cancer patients receiving chemotherapy assessing patient-related, chemotherapy-related and genetic risk factors

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Pfeil, Alena M ^a   Vulsteke, Christof ^b,c   Paridaens, Robert ^b,c   Dieudonné, Anne Sophie ^b,c   Pettengell, Ruth ^d   Hatse, Sigrid ^b,c   Neven, Patrick ^c   Lambrechts, Diether ^e,f   Szucs, Thomas D ^a   Schwenkglenks, Matthias ^a   Wildiers, Hans ^c  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^e DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^f UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Breast neoplasms; Chemotherapy; Febrile neutropenia; Genetics; Multivariable analysis; Single nucleotide polymorphism

Indexed keywords

ALANINE AMINOTRANSFERASE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FIBROBLAST GROWTH FACTOR RECEPTOR 4; FLUOROURACIL; HEMOGLOBIN; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1;

ADULT; ALLELE; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; FEBRILE NEUTROPENIA; FEMALE; GENE FREQUENCY; GENETIC RISK; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTIVE VALUE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE COUNT;

ADULT; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; EARLY DIAGNOSIS; FEBRILE NEUTROPENIA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84899069233     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-201     Document Type: Article

References (36)

1. Hasset MJ, O'Malley AJ, Pakes JR, Newhouse JP, Earle CC. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 2006, 98(16):1108-1117. doi:10.1093/jnci/djj305, 10.1093/jnci/djj305, 16912263.
2. Klastersky J, Paesmans M. Risk-adapted strategy for the management of febrile neutropenia in cancer patients. Support Care Cancer 2007, 15:477-482. doi:10.1007/s00520-006-0185-8, 10.1007/s00520-006-0185-8, 17294227.
3. Schwenkglenks M, Jackisch C, Constenla M, Kerger JN, Paridaens R, Auerbach L, Bosly A, Pettengell R, Szucs TD, Leonard R. Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment. Support Care Cancer 2006, 14(9):901-909. doi:10.1007/s00520-006-0034-9, 10.1007/s00520-006-0034-9, 16622653.
4. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006, 106(10):2258-2266. doi:10.1002/cncr.21847, 10.1002/cncr.21847, 16575919.
5. Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J, Weber DC, Zielinski C. European Organisation for Research and Treatment of Cancer. 2010 update of EORTC guidelines for the use of granulocyte colony-stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011, 47(1):8-32. doi:10.1016/j.ejca.2010.10.013, 10.1016/j.ejca.2010.10.013, 21095116.
6. Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK, Kuderer NM, Langston AA, Marr KA, Rolston KV, Ramsey SD. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American society of clinical oncology clinical practice guideline. J Clin Oncol 2013, 31(6):794-810. doi:10.1200/JCO.2012.45.8661, 10.1200/JCO.2012.45.8661, 23319691.
7. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC. 2006 Update of recommendations for the Use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006, 24(19):3187-3205. doi:10.1200/JCO.2006.06.4451, 10.1200/JCO.2006.06.4451, 16682719.
8. Crawford J, Caserta C, Roila F. Hematopoietic growth factors: ESMO clinical practice guidelines for the applications. Ann Oncol 2010, 21(Suppl 5):v248-v251. doi:10.1093/annonc/mdq195.
9. Schwenkglenks M, Pettengell R, Jackisch C, Paridaens R, Constenla M, Bosly A, Szucs TD, Leonard R. Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study. Support Care Cancer 2011, 19(4):483-490. doi:10.1007/s00520-010-0840-y, 10.1007/s00520-010-0840-y, 20306092.
10. Jenkins P, Freeman S. Pretreatment haematological laboratory values predict for excessive myelosuppression in patients receiving adjuvant FEC chemotherapy for breast cancer. Ann Oncol 2009, 20(1):34-40. doi:10.1093/annonc/mdn560.
11. Lyman GH, Kuderer NM, Crawford J, Wolff DA, Culakova E, Poniewierski MS, Dale DC. Predicting individual risk of neutropenic complications in patients receiving cancer chemotherapy. Cancer 2011, 117(9):1917-1927. doi:10.1002/cncr.25691, 10.1002/cncr.25691, 3640637, 21509769.
12. López-Pousa A, Rifà J, Casas De Tejerina A, González-Larriba JL, Iglesias C, Gasquet JA, Carrato A, DELFOS Study Group Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumours. Eur J Cancer Care (Engl) 2010, 19(5):648-655. 10.1111/j.1365-2354.2009.01121.x, 3082427, 20088918, DELFOS Study Group.
13. Hosmer W, Malin J, Wong M. Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancer. Support Care Cancer 2011, 19(3):333-341. doi:10.1007/s00520-010-0821-1, 10.1007/s00520-010-0821-1, 3046362, 20179995.
14. Okishiro M, Kim SJ, Tsunashima R, Nakayama T, Shimazu K, Shimomura A, Maruyama N, Tamaki Y, Noguchi S. MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide. Breast Cancer Res Treat 2012, 132(3):947-953. doi:10.1007/s10549-011-1637-5, 10.1007/s10549-011-1637-5, 21706156.
15. Low SK, Kiyotani K, Mushiroda T, Daigo Y, Nakamura Y, Zembutsu H. Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients. J Hum Genet 2009, 54(10):564-571. doi:10.1038/jhg.2009.79, 10.1038/jhg.2009.79, 19696793.
16. Tang NL, Liao CD, Wang X, Mo FK, Chan VT, Ng R, Pang E, Suen JJ, Woo J, Yeo W. Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients. J Cancer Res Clin Oncol 2013, 139(3):419-427. doi:10.1007/s00432-012-1345-5, 10.1007/s00432-012-1345-5, 23143606.
17. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events. Version 3.0, DCTD, NCI, NIH, DHHS. http://ctep.cancer.gov. Accessed 14 April 2013.
18. Vulsteke C, Lambrechts D, Dieudonné A, Hatse S, Brouwers B, van Brussel T, Neven P, Belmans A, Schöffski P, Paridaens R, Wildiers H. Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC). Ann Oncol 2013, 24(6):1513-1525. doi:10.1093/annonc/mdt008, 10.1093/annonc/mdt008, 23396606.
19. Sun L, Craiu RV, Paterson AD, Bull SB. Stratified false discovery control for large-scale hypothesis testing with application to genome-wide association studies. Genet Epidemiol 2006, 30(6):519-30. doi:10.1002/gepi.20164, 10.1002/gepi.20164, 16800000.
20. Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. Source Code for Biol Med 2008, 3:17. doi:10.1186/1751-0473-3-17.
21. Hosmer DW, Lemeshow S. A goodness-of-fit test for the multiple logistic regression model. Commun Stat 1980, A10:1043-1069.
22. Mooney CZ, Duval RD. Bootstrapping: A Nonparametric Approach to Statistical Inference Newbury Park, CA: Sage.
23. Rakha EA, El-Sayed ME, Lee AH, Elston CW, Grainge MJ, Hodi Z, Blamey RW, Ellis IO. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma. J Clin Oncol 2006, 26(19):3153-3158. doi:10.1200/JCO.2007.15.5986.
24. Wittekind C, Meyer HJ. TNM Klassifikation maligner Tumoren 2010, Cooperation with the International Union Against Cancer (UICC), 7.
25. Brouckaert O, Laenen A, Vanderhaegen J, Wildiers H, Leunen K, Amant F, Berteloot P, Smeets A, Paridaens R, Christiaens MR, Floris G, Moerman P, Van Limbergen E, Peeters S, Weltens C, Vergote I, Neven P. Applying the 2011 St Gallen panel of prognostic markers on large single hospital cohort of consecutively treated primary operable breast cancers. Ann Oncol 2012, 23(10):2578-2584. doi:10.1093/annonc/mds062, 10.1093/annonc/mds062, 22492698.
26. Lee AH, Ellis IO. The Nottingham prognostic index for invasive carcinoma of the breast. Pathol Oncol Res 2008, 14(2):113-115. doi:10.1007/s12253-008-9067-3, 10.1007/s12253-008-9067-3, 18543079.
27. Moreau M, Klastersky J, Schwarzbold A, Muanza F, Georgala A, Aoun M, Loizidou A, Barette M, Costantini S, Delmelle M, Dubreucg L, Vekemans M, Ferrant A, Bron D, Paesmans M. A general chemotherapy myelotoxicity score to predict febrile neutropenia in haematological malignancies. Ann Oncol 2009, 20(3):513-519. doi:10.1093/annonc/mdn655.
28. Wan S, Lai Y, Myers RE, Li B, Palazzo JP, Burkart AL, Chen G, Xing J, Yang H. Post-diagnosis haemoglobin change associates with overall survival of multiple malignancies - results from a 14-year hospital-based cohort of lung, breast, colorectal, and liver cancers. BMC Cancer 2013, 13:340. 10.1186/1471-2407-13-340, 3710492, 23841898.
29. Culakova E, Wolff DA, Poniewierksi MS, Crawford J, Dale DC, Lyman GH. Factors related to neutropenic events in early stage breast cancer patients [abstract]. J Clin Oncol 2008, 26(Suppl):634.
30. Hladnik M, Wills AR, Augustin KM. Systemic chemotherapy: special considerations 2007, 30-32. Lippincott Williams and Wilkins, second edition, The Washington manual of oncology.
31. Semsei AF, Erdelyi DJ, Ungvari I, Csagoly E, Hegyi MZ, Kiszel PS, Lautner-Csorba O, Szabolcs J, Masat P, Fekete G, Falus A, Szalai C, Kovacs GT. ABCC1 polymorphisms in anthracycline induced cardiotoxicity in childhood acute lymphoblastic leukemia. Cell Biol Int 2012, 36(1):79-86. doi:10.1042/CBI20110264, 10.1042/CBI20110264, 21929509.
32. Visscher H, Ross CJ, Rassekh SR, Barhdadi A, Dubé MP, Al-Saloos H, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Paal HJ, Brown AM, Rogers PC, Phillips MS, Rieder MJ, Carleton BC, Hayden MR, Canadian Pharmacogenomics Network for Drug Safety Consortium Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol 2012, 30(13):1422-1428. doi:10.1200/JCO.2010.34.3467, 10.1200/JCO.2010.34.3467, 21900104, Canadian Pharmacogenomics Network for Drug Safety Consortium.
33. Wojnowski L, Kulle B, Schirmer M, Schlüter G, Schmidt A, Rosenberger A, Vonhof S, Bickeböller H, Toliat MR, Suk EZ, Tzvetkov M, Kruger A, Seifert S, Kloess M, Hahn H, Loeffler M, Nürnberg P, Pfreundschuh M, Trümper L, Brockmöller J, Hasenfuss. GNAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005, 112(24):3754-3762. 10.1161/CIRCULATIONAHA.105.576850, 16330681.
34. Pettengell R, Bosly A, Szucs TD, Jackisch C, Leonard R, Paridaens R, Constenla M, Schwenkglenks M, Impact of Neutropenia in Chemotherapy-European Study Group (INC-EU) Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. Br J Haematol 2009, 144(5):677-685. doi:10.1111/j.1365-2141.2008.07514.x, 10.1111/j.1365-2141.2008.07514.x, 2680267, 19055662, Impact of Neutropenia in Chemotherapy-European Study Group (INC-EU).
35. Altman DG, Royston P. What do we mean by validating a prognostic model?. Stat Med 2000, 19(4):453-473. doi:10.1002/(SICI)1097-0258(20000229)1, 10.1002/(SICI)1097-0258(20000229)19:4<453::AID-SIM350>3.0.CO;2-5, 10694730.
36. Schwenkglenks M, Bendall KL, Pfeil AM, Szabo Z, Pettengell R. External validation of a risk model of febrile neutropenia occurrence in non-Hodgkin lymphoma patients. Leuk Lymphoma 2013, doi:10.3109/10428194.2013.780287 [Epub ahead of print].